Afficher la couverture 'Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells | Fonteneau, Jean-François' en grand format
/5

0 avis

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells

Archive ouverte

Fonteneau, Jean-François | Guillerme, Jean-Baptiste | Tangy, Frédéric | Grégoire, Marc

Edité par CCSD ; Taylor & Francis -

International audience. Attenuated measles viruses (MV) are assessed in clinical trials for their capacity to preferentially infect and kill tumor cells. We recently showed that MV-infected tumor cells are able to activate tumor antigen cross-presentation by myeloid and plasmacytoid dendritic cells. Thus, MV-based antitumor virotherapy may stimulate antitumor immune response.

Consulter en ligne

Suggestions

Du même auteur

Recent Progresses of Oncolytic Immunotherapy

Archive ouverte | Fonteneau, Jean-François | CCSD

International audience. Oncolytic immunotherapy, also known as anti-tumor virotherapy, is a therapeutic approach using oncolytic viruses that preferentially or exclusively infect and kill tumor cells. In this short ...

Oncolytic Viruses and Immune Checkpoint Inhibitors

Archive ouverte | Fonteneau, Jean-François | CCSD

International audience. no abstract

Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

Archive ouverte | Achard, Carole | CCSD

International audience. Attenuated measles virus (MV) is currently being evaluated in clinical trials as an oncolytic therapeutic agent. Originally used for its lytic activity against tumor cells, it is now admitted...

Chargement des enrichissements...